发明名称 Substituted anilides
摘要 The invention is directed to physiologically active compounds of formula (I):wherein:R1 is hydrogen, halogen, hydroxy, lower alkyl or lower alkoxy;X1, X2 and X6 independently represent N or CR10; andone of X3, X4 and X5 represents CR11 and the others independently represents N or CR10;where R10 is hydrogen, amino, halogen, hydroxy, lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulphinyl, lower alkylsulphonyl, nitro or trifluoromethyl; and R11 represents a group -L1-Ar1-L2-Y; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates of such compounds and their N-oxides and prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (alpha4beta1).
申请公布号 US6479519(B1) 申请公布日期 2002.11.12
申请号 US20000558812 申请日期 2000.04.26
申请人 AVENTIS PHARMA LIMITED 发明人 ASTLES PETER CHARLES;CLARK DAVID EDWARD;COLLIS ALAN JOHN;COX PAUL JOSEPH;EASTWOOD PAUL ROBERT;HARRIS NEIL VICTOR;QUAI LAI JUSTINE YEUN;MORLEY ANDREW DAVID;PORTER BARRY
分类号 C07D295/14;A61K31/19;A61K31/381;A61K31/42;A61K31/44;A61K31/4427;A61K31/443;A61K31/4433;A61K31/4436;A61K31/4439;A61K31/445;A61K31/495;A61K31/496;A61K31/4965;A61K31/501;A61P11/06;A61P19/02;A61P43/00;C07C275/42;C07C311/06;C07D211/62;C07D213/71;C07D213/75;C07D213/79;C07D213/81;C07D213/82;C07D213/89;C07D233/84;C07D237/24;C07D261/10;C07D261/18;C07D295/16;C07D309/06;C07D333/38;C07D333/40;C07D401/12;C07D405/12;C07D409/12;(IPC1-7):C07C275/38;C07C275/40;A61K31/17 主分类号 C07D295/14
代理机构 代理人
主权项
地址